Search results for "OBESITY"

showing 10 items of 1833 documents

In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters

2016

Backgrounds and aims: Low concentrations of plasma HDL-C are associated with the development of atherosclerotic cardiovascular diseases and type 2 diabetes. Here we aimed to explore the relationship between the in vivo fractional synthesis of triglycerides (fTG) in subcutaneous (s.q.) abdominal adipose tissue (AT), HDL-C concentrations and HDL particle size composition in non-diabetic humans. Methods: The fTG in s.q. abdominal AT was measured in 16 non-diabetic volunteers (7 women, 9 men; Age: 49 ± 20 years; BMI: 31 ± 5 kg/m; Fasting Plasma Glucose: 90 ± 10 mg/dl) after 2H2O labeling. HDL-C concentration and subclasses, large (L-HDL), intermediate (I-HDL) and small (S-HDL) were measured. Re…

Blood GlucoseMale0301 basic medicinemedicine.medical_specialtyAdipocyte; Atheroprotective; Gender-related; HDL-C metabolism; Mass spectrometry; Stable isotope tracer kinetics; Triglycerides; Cardiology and Cardiovascular MedicineAdipose tissueWhite adipose tissueType 2 diabetes030204 cardiovascular system & hematologyTriglycerideArticleAtheroprotective03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceIn vivoInternal medicineAdipocytemedicineHumansObesityTriglyceridesAgedHDL-C metabolismAdipocyteStable isotope tracer kineticMass spectrometrybusiness.industryLipogenesisCholesterol HDLnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseLipidsObesitySubcutaneous Fat AbdominalGender-related030104 developmental biologyEndocrinologychemistryLipogenesisFemalelipids (amino acids peptides and proteins)Insulin ResistanceCardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance

2017

Low-grade inflammation links obesity to insulin resistance through the activation of tissue-infiltrating immune cells. Interleukin-6 (IL-6) is a crucial regulator of T cells and is increased in obesity. Here we report that classical IL-6 signalling in T cells promotes inflammation and insulin resistance during the first 8 weeks on a high-fat diet (HFD), but becomes dispensable at later stages (after 16 weeks). Mice with T cell-specific deficiency of IL-6 receptor-α (IL-6RαT-KO) exposed to a HFD display improved glucose tolerance, insulin sensitivity and inflammation in liver and EWAT after 8 weeks. However, after 16 weeks, insulin resistance in IL-6RαT-KO epididymal white adipose tissue (EW…

Blood GlucoseMale0301 basic medicinemedicine.medical_specialtyTime FactorsT-LymphocytesT cellScienceGeneral Physics and AstronomyInflammationWhite adipose tissueBiologyDiet High-FatArticleGeneral Biochemistry Genetics and Molecular BiologyMice03 medical and health sciences0302 clinical medicineInsulin resistanceImmune systemInternal medicinemedicineAnimalsHomeostasisObesityReceptorInflammationMice KnockoutMultidisciplinaryInterleukin-6QGeneral ChemistryT lymphocyteLipid Metabolismmedicine.diseaseReceptors Interleukin-6030104 developmental biologymedicine.anatomical_structureEndocrinology030220 oncology & carcinogenesisInsulin Resistancemedicine.symptomHomeostasisSignal TransductionNature Communications
researchProduct

ERK1 and ERK2 activation modulates diet-induced obesity in mice

2017

IF 3.112; International audience; Obesity is a worldwide problem, and dietary lipids play an important role in its pathogenesis. Recently, Erk1 knock-out (ERK1(-/-)) mice have been shown to exhibit low preference for dietary fatty acids. Hence, we maintained Erk1(-/-) mice on a high-fat diet (HFD) to assess the implication of this mitogen-activated protein (MAP) kinase in obesity. The Erk1(-/-) mice, fed the HFD, were more obese than wild-type (WT) animals, fed the same diet. Erk1(-/-) obese mice gained more fat and liver mass than WT obese animals. No difference was observed in daily food and energy intake in HFD-fed both group of animals. However, feed efficiency was higher in Erk1(-/-) t…

Blood GlucoseMale0301 basic medicinemedicine.medical_treatmentMice ObeseBiochemistryMicechemistry.chemical_compoundPhosphorylationBeta oxidationCells CulturedMice KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Reverse Transcriptase Polymerase Chain ReactionGeneral MedicineLipidsFatty acid synthaseLiverLipogenesisHomeostatic model assessmentmedicine.medical_specialtyBlotting WesternBiologyDiet High-FatReal-Time Polymerase Chain Reaction03 medical and health sciencesInsulin resistanceInternal medicinemedicineAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyRNA MessengerObesity[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyInflammationTriglycerideLipogenesisInsulinBody WeightLipid Metabolismmedicine.diseaseObesityMice Inbred C57BL030104 developmental biologyEndocrinologychemistrybiology.proteinMAP kinaseInsulin ResistanceBiochimie
researchProduct

Evidence for hypothalamic ketone bodies sensing: impact on food intake and peripheral metabolic responses in mice

2016

Monocarboxylates have been implicated in the control of energy homeostasis. Among them, the putative role of ketone bodies produced notably during high-fat diet (HFD) has not been thoroughly explored. In this study, we aimed to determine the impact of a specific rise in cerebral ketone bodies on food intake and energy homeostasis regulation. A carotid infusion of ketone bodies was performed on mice to stimulate sensitive brain areas for 6 or 12 h. At each time point, food intake and different markers of energy homeostasis were analyzed to reveal the consequences of cerebral increase in ketone body level detection. First, an increase in food intake appeared over a 12-h period of brain keton…

Blood GlucoseMale0301 basic medicineobesitynervous-systemPhysiology[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionEndocrinology Diabetes and MetabolismKetone BodiesEnergy homeostasisEatingMicebodiesHomeostasisGlucose homeostasisoxidative stressAgouti-Related ProteinNeuropeptide YPhosphorylationmonocarboxylate transporters2. Zero hunger[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]fat massHypothalamusKetone bodiesStarvation responseketogenic mediterranean dietweight-lossmedicine.medical_specialtybeta-hydroxybutyrateHypothalamusBiologyDiet High-Fat03 medical and health sciencesInsulin resistancerat-brainPhysiology (medical)Internal medicinemedicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Animalsglucose homeostasisAdenylate Kinase/metabolism; Agouti-Related Protein/metabolism; Animals; Blood Glucose; Diet High-Fat; Eating/drug effects; Eating/physiology; Energy Metabolism/drug effects; Energy Metabolism/physiology; Gluconeogenesis/drug effects; Gluconeogenesis/physiology; Homeostasis; Hypothalamus/drug effects; Hypothalamus/metabolism; Insulin Resistance/physiology; Ketone Bodies/pharmacology; Male; Mice; Mice Inbred C57BL; Neuropeptide Y/metabolism; Phosphorylation/drug effectsenergy homeostasisAdenylate KinaseGluconeogenesismedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyGluconeogenesislow-carbohydrateInsulin ResistanceEnergy Metabolism[SDV.AEN]Life Sciences [q-bio]/Food and NutritionHomeostasis
researchProduct

Eating Competence of Elderly Spanish Adults Is Associated with a Healthy Diet and a Favorable Cardiovascular Disease Risk Profile

2010

Eating competence (EC), a bio-psychosocial model for intrapersonal approaches to eating and food-related behaviors, is associated with less weight dissatisfaction, lower BMI, and increased HDL-cholesterol in small U.S. studies, but its relationship to nutrient quality and overall cardiovascular risk have not been examined. Prevención con Dieta Mediterránea (PREDIMED) is a 5-y controlled clinical trial evaluating Mediterranean diet efficacy on the primary prevention of cardiovascular diseases (CVD) in Spain. In a cross-sectional study, 638 PREDIMED participants (62% women, mean age 67 y) well phenotyped for cardiovascular risk factors were assessed for food intake and EC using validated ques…

Blood GlucoseMaleAgingmedicine.medical_specialtyMediterranean dietCross-sectional studyMedicine (miscellaneous)Blood sugarBody Mass Indexlaw.inventionEatingRandomized controlled trialRisk FactorslawMediterranean dietSurveys and QuestionnairesInternal medicineHumansMedicineSingle-Blind MethodMetabolic systemAgedNutrition and Dieteticsbusiness.industryPREDIMED studymedicine.diseaseObesityDietClinical trialCholesterolCross-Sectional StudiesEndocrinologyBlood chemistryCardiovascular DiseasesSpainFemaleRandomized trialbusinessBody mass indexThe Journal of Nutrition
researchProduct

Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endotheli…

2015

Endothelial dysfunction plays a key role in obesity-induced risk of cardiovascular disease. The aim of the present study was to analyze the effect of chronic peroxisome proliferator-activated receptor (PPAR)β/δ agonist GW0742 treatment on endothelial function in obese mice fed a high-fat diet (HFD).Five-week-old male mice were allocated to one of the following groups: control, control-treated (GW0742, 3 mg/kg per day, by oral gavage), HFD, HFD + GW0742, HFD + GSK0660 (1 mg/kg/day, intraperitoneal) or HFD-GW0742-GSK0660 and followed for 11 or 13 weeks. GW0742 administration to mice fed HFD prevented the gain of body weight, heart and kidney hypertrophy, and fat accumulation. The increase in …

Blood GlucoseMaleAgonistmedicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumPhysiologymedicine.drug_classCaveolin 1Peroxisome proliferator-activated receptorThiophenesDiet High-FatGW0742MiceInsulin resistanceInternal medicineInternal MedicinemedicineAnimalsObesityPPAR deltaSulfonesEndothelial dysfunctionReceptorPPAR-betaAortachemistry.chemical_classificationInterleukin-6Tumor Necrosis Factor-alphabusiness.industryGlucose Tolerance TestPeroxisomemedicine.diseaseToll-Like Receptor 4VasodilationThiazolesEndocrinologymedicine.anatomical_structureAdipose TissuechemistryHypertensionAdiponectinEndothelium VascularInsulin ResistanceReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

The impact of maternal weight in pregnancy on glucose metabolism in non-diabetic offspring in late adulthood

2019

Aims: We aimed to examine the association between maternal adiposity and glucose metabolism in adult offspring without diabetes, simultaneous taking offspring own adiposity into account. Methods: This longitudinal birth cohort study (Helsinki Birth Cohort Study) included 1,440 non-diabetic subjects examined at a mean age of 62 years. Subjects were divided into quartiles according to maternal body mass index (BMI). The impact of maternal BMI on offspring body composition was also studied. Results: There were no differences in fasting glucose between the groups. In men, maternal BMI was inversely associated with mean 2-hour glucose concentration after a 75 g oral glucose tolerance test (p <0.…

Blood GlucoseMaleEndocrinology Diabetes and MetabolismCHILDHOODPhysiologyraskausOverweightCohort Studies0302 clinical medicineEndocrinologyPregnancyMedicineMass indexLongitudinal StudiesMUSCLE MASS030212 general & internal medicineaineenvaihduntaRISK2. Zero hungerGlucose metabolismINSULIN-RESISTANCEylipainoGeneral MedicineInsulin sensitivityäiditGestational Weight Gainmaternal obesityOBESITYAdult ChildrenFemaleHEALTHmedicine.symptomAdultOffspringglucose metabolismOffspring health030209 endocrinology & metabolismBMI03 medical and health sciencesaineenvaihduntahäiriötInsulin resistanceMaternal obesityDiabetes mellitusInternal MedicineHumansinsulin sensitivitylapset (perheenjäsenet)offspring healthPregnancyOVERWEIGHTbusiness.industrynutritional and metabolic diseasesinsuliiniresistenssimedicine.diseaseBODY-MASS INDEXPANCREATIC BETA-CELL3121 General medicine internal medicine and other clinical medicineLean body masslihavuusGAINbusinessBody mass indexDiabetes Research and Clinical Practice
researchProduct

Adiponectin, resistin and leptin in paediatric chronic renal failure: Correlation with auxological and endocrine profiles

2013

Introduction: Chronic renal failure (CRF) compromises nutrition, growth, puberty, glycometabolic homeostasis, and adipokine secretion (i.e. adiponectin, resistin, and leptin). Adipokines play a role in the clinical outcome, but data in paediatric patients is scant. Aim: To evaluate the link between kidney function, adiponectin, resistin, leptin, hormonal status, nutritional state and late outcome of CRF children. Materials and methods: We studied leptin, adiponectin and resistin levels in 31 CRF patients (19 males, 12 females, aged 12.1 ± 4.47 years) managed conservatively, and 30 healthy age- and gender-matched controls. Clinical, auxological, biochemical, hormonal data, glucose and insuli…

Blood GlucoseMaleLeptinmedicine.medical_specialtyTime FactorsAdolescentAdolescent Nutritional Physiological Phenomenamedicine.medical_treatmentNutritional StatusRenal functionAdipokineHOMA-IRchemistry.chemical_compoundSettore MED/38 - Pediatria Generale E SpecialisticaRisk FactorsInternal medicineAdipokinemedicineChronic renal failureHumansInsulinResistinObesityChildGlycated HemoglobinCreatinineAdiponectinbusiness.industryInsulinLeptinAge Factorsnutritional and metabolic diseasesPrognosismedicine.diseaseObesityEndocrinologychemistryCardiovascular DiseasesNephrologyCase-Control StudiesDisease ProgressionKidney Failure ChronicFemaleResistinAdiponectinInsulin ResistancebusinessBiomarkershormones hormone substitutes and hormone antagonists
researchProduct